22 May 2025
Genetic testing has enabled faster and more precise understanding of which patients may benefit from new and existing treatments. With robust genomic data, biopharmaceutical companies can better understand the genetic prevalence of rare diseases and collaborate with healthcare providers to increase access to therapeutic options for their patients.
Labcorp, now including Invitae and Prognos, is committed to helping life sciences teams with genomic insights that drive clinical development and support the commercialization of therapies for patients living with rare diseases. In Part 1 of this webinar series, Labcorp and Prognos discuss the clinical utility of genetic testing and the opportunities and challenges around variant classification. Labcorp’s innovative approach to classification of variants of uncertain significance (VUS) reduces uncertainty in genetic testing and provides actionable results to inform engagement with healthcare providers.
What is covered in this webinar?
- Leveraging genetic testing data for clinical and commercial use cases
- The complexities around variant classification and its impact on provider engagement
- Labcorp’s innovative approach to minimizing uncertainty in genetic testing
Access the full Recording
Submit the form to watch this on-demand session. Discover how real-world data, combined with genomic insights, can help accelerate access to targeted treatments.